早期肺癌立体定向放疗前是否必须活检:配对队列分析
本研究纳入2009年7月至2017年7月接受肺部病灶SBRT的患者,将131例基于临床诊断(PET/CT高代谢、连续CT示肿块增大,且不适合/拒绝活检或活检无结论)的患者与131例病理确诊患者进行配对比较。3年总生存、局部控制、区域及远处复发均无显著差异,但病理诊断组远处复发有增多趋势;把握度计算提示需多中心数据以排除5%–15%良性病变接受治疗带来的结局差异。
要点
- 临床诊断组与病理诊断组SBRT后3年生存及复发模式无显著差异。
- 病理诊断组远处复发呈增多趋势(HR 0.6,95%CI 0.3-1.1)。
- 需多中心数据排除临床诊断中5%–15%良性病变对结局的影响。
核心结论
- 在本研究中,临床诊断与病理诊断患者接受肺部SBRT后的复发模式和生存无临床显著差异。
- 病理诊断组远处复发有增多趋势。
研究设计与样本
- 单中心配对队列分析,纳入2009年7月至2017年7月因单个肺部病灶接受SBRT的患者。
- 131例临床诊断患者与131例病理诊断患者按患者、治疗和肿瘤特征进行配对。
- 进行了把握度计算以估计检测无病理组5%或15%良性病变率所致差异所需的样本量。
主要发现
- 2009至2017年间878例患者共接受924次肺部SBRT,其中131例基于临床发现接受治疗。
- 3年总生存HR 1.2(95%CI 0.7-2.1),局部控制HR 0.9(95%CI 0.4-2),均无显著差异。
- 3年区域复发HR 0.5(95%CI 0.2-1.4),远处复发HR 0.6(95%CI 0.3-1.1),均无显著差异。
临床怎么用
- 对于不适合活检、拒绝活检或活检无结论但影像学高度怀疑恶性的早期NSCLC患者,可考虑直接行SBRT。
- 临床诊断组与病理诊断组SBRT后的生存和复发结局相似,支持在特定患者中免于活检。
局限性
- 为单中心配对队列分析,样本量有限。
- 把握度计算提示需多中心数据才能排除5%–15%良性病变接受治疗所致的结局差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: For nonoperable stage I non-small cell lung cancer, stereotactic body radiation therapy (SBRT) has emerged as a standard treatment option. We aimed to compare the clinical outcomes of lung SBRT between patients with versus without pathologic cancer diagnosis. METHODS AND MATERIALS: We included patients treated by SBRT for a single pulmonary lesion between July 2009 and July 2017. Patients in the clinical diagnosis group had a positron emission tomography/computed tomography scan showing hypermetabolism, growth of the mass on sequential computed tomography, and were not eligible for biopsy, refused biopsy, or had an inconclusive biopsy. For each of those patients, a matched pair in the pathologic diagnosis group was identified by matching for patient, treatment, and tumoral characteristics. We performed a power calculation to estimate the sample size required to detect a difference arising from a 5% or 15% rate of benign processes in the group without pathology. RESULTS: A total of 924 lung SBRT treatments were performed among 878 patients from 2009 to 2017. Within this population, 131 patients were treated based on clinical findings. They were matched with 131 patients with a pathologic diagnosis who received treatment. At 3 years, no significant differences were observed in overall survival (hazard ratio [HR], 1.2; 95% confidence interval [CI], 0.7-2.1), local control (HR, 0.9; 95% CI, 0.4-2), or regional (HR, 0.5; 95% CI, 0.2-1.4) or distant recurrence (HR, 0.6; 95% CI, 0.3-1.1). CONCLUSIONS: In our population, we found no clinically significant difference in patterns of recurrence or survival after lung SBRT for patients who had received clinical versus pathological diagnoses. There was, however, a trend toward more distant recurrences in the pathologic diagnosis group. Our power calculation suggests that data from multiple institutions would be required to rule out a difference in outcomes due to 5% to 15% of clinically diagnosed cases being treated for benign processes.
引用
- Dautruche A, Filion E, Mathieu D, et al. To Biopsy or Not to Biopsy?: A Matched Cohort Analysis of Early-Stage Lung Cancer Treated with Stereotactic Radiation with or Without Histologic Confirmation. Int J Radiat Oncol Biol Phys. 2020. PMID: 32004581. doi:10.1016/j.ijrobp.2020.01.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。